Trinity Pierce, Author at Germfree

Germfree Appoints Carol Houts as Chief Executive Officer

Trinity Pierce — Tue, 24 Mar 2026 11:33:21 +0000

Germfree Appoints Carol Houts as Chief Executive Officer

- Carol Houts brings 30 years of healthcare and life sciences leadership to Germfree’s next phase of growth and execution.

“What we have built at Germfree, the partnerships, the platform, and the pipeline puts us in a strong position to lead this industry forward,” said Carol Houts, Chief Executive Officer of Germfree Laboratories.

Ormond Beach, FL, March 24, 2026 — Germfree Laboratories (“Germfree”), a leading provider of integrated cGMP infrastructure, equipment, and services for advanced therapies and hospital manufacturing, today announced the appointment of Carol Houts as Chief Executive Officer. Kevin Kyle, Germfree’s previous CEO, will transition to an advisory role with Germfree and EW Healthcare Partners.

Carol brings 30 years of healthcare and life sciences experience to the role, with a career spanning clinical development, global regulatory strategy, cGMP operations, quality systems, and commercial leadership at organizations including Pfizer, Stryker Biotech, and CROs executing clinical trials globally. At Germfree, she has been serving as Chief Commercial & Strategy Officer and member of the Board, where she has helped shape the company’s strategic growth agenda and expand its partnerships across pharmaceutical and healthcare markets. During her tenure, she has led key commercial initiatives across decentralized manufacturing, global partnerships, and the company’s expanding solutions portfolio, including pharmaceutical isolators, Smarthood IV workflow systems, and mobile and modular GMP platforms.

As CEO, Carol will focus on strengthening execution, operational performance, and scaling Germfree’s services capabilities to support a growing global customer base. With the commercial launch of Smarthood and increasing demand for Germfree’s isolator and modular GMP solutions, the company is entering a significant new phase of growth. Germfree is currently delivering some of its most complex turnkey programs to date, including purpose-built ATMP manufacturing solutions designed to be operationally ready from day one.

“What we have built at Germfree, the partnerships, the platform, and the pipeline puts us in a strong position to lead this industry forward,” said Carol Houts, Chief Executive Officer of Germfree Laboratories. “My focus is on deepening the customer relationships at our core, relentless focus on execution, and scaling our services capabilities across the full portfolio from advanced therapy manufacturing to hospital pharmacy and beyond.”

“We are excited to have Carol at the helm of Germfree,” said Evis Hursever, Ph.D., Chief Executive Officer of EW Healthcare Partners. “Over nearly a decade, she has been at the center of Germfree’s commercial growth, helping build the partnerships, platform, and pipeline that define the company today. She brings the operational discipline and strategic clarity needed to scale the business, making her the ideal choice to lead the company as it enters this next phase of growth. EW Healthcare Partners is fully committed to supporting Germfree’s ambitious plans.”

“The board and I are thrilled to welcome Carol as Germfree’s CEO,” said Andy Thomson, Chair of the Board of Germfree and Operating Partners with EW Healthcare Partners. “Carol is a seasoned global healthcare executive who brings tremendous experience and knowledge in commercial and operation excellence. Her expertise and leadership will be critical in successfully executing the ambitious commercial and operational plan as Germfree strives in its mission as the partner of choice in the manufacturing of advanced therapies.”

“Over nearly a decade, she has been at the center of Germfree’s commercial growth, helping build the partnerships, platform, and pipeline that define the company today. She brings the operational discipline and strategic clarity needed to scale the business, making her the ideal choice to lead the company as it enters this next phase of growth. EW Healthcare Partners is fully committed to supporting Germfree’s ambitious plans.” said Evis Hursever, Ph.D., CEO of EW Healthcare Partners.

About Germfree Laboratories

Germfree advances ATMP development and point-of-care manufacturing by delivering U.S-designed and built, ready-to-operate modular and mobile CGMP cleanrooms, integrated equipment, and lifecycle services under a single contract. Today, more than 200 Germfree laboratories, cleanrooms, and complex equipment systems operate in 32 countries, underscoring the company’s commitment to innovative, agile, integrated, and impactful research and biomanufacturing worldwide. Strategic partnerships with process-technology leaders and in-country service firms ensure every deployment arrives fully validated, operationally ready, and regulatory compliant from day one. The company’s U.S. manufacturing hub and on-site service programs ensure rapid deployment, sustained performance, knowledge transfer to local workforces and a continuous pipeline of innovation that keeps facilities future ready as advanced therapies evolve. Learn more at www.germfree.com.

About EW Healthcare Partners (“EW”)

With over $4 billion raised since inception, EW Healthcare Partners is one of the largest and oldest private healthcare investment firms and seeks to make growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. Since its founding in 1985, EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been a long-term investor in over 150 healthcare companies, ranging across sectors, stages and geographies. The team is comprised of over 20 senior investment professionals with offices in New York, London and Houston. For more information, visit www.ewhealthcare.com.

SOURCE Germfree Laboratories LLC

Media Contacts:
Germfree Laboratories
Dex Williams, Director of Go-To-Market Operations
marketing@germfree.com

About Germfree

Germfree Laboratories LLC. creates environments that serve life science innovation and advance global health. The company, founded in 1962, designs, engineers and manufactures flexible cGMP-compliant cleanroom facilities and mobile units, as well as high containment laboratories, which are process-ready, upon deployment.

The post Germfree Appoints Carol Houts as Chief Executive Officer appeared first on Germfree.

Celebrating Retirement: Ghislain Beauregard’s Legacy and the Future of Arcoplast

Trinity Pierce — Wed, 13 Aug 2025 15:43:58 +0000

Celebrating Retirement: Ghislain Beauregard’s Legacy and the Future of Arcoplast

- As Arcoplast enters a new chapter, we pause to honor the remarkable journey of its founder, Ghislain Beauregard, who is stepping into retirement on August 15th, 2025 after decades of innovation, leadership, and an unwavering commitment to excellence.

From his early days as an interior contractor to pioneering architectural finishes for high-containment environments, Ghislain’s story is one of vision and grit. What began with a simple request from IBM for a low-maintenance wall system evolved into a revolutionary idea—transforming industrial-grade polymers into architectural solutions.

That spark led to the birth of Arcoplast.

Despite early skepticism and industry challenges, Ghislain saw potential where others didn’t. He focused on sectors where performance mattered most—dairy, food production, and high-containment environments—and built a company that didn’t just meet expectations but redefined them.

“I’m proud that we’ve built something truly unique; products others don’t dare attempt,” Ghislain shared. “We shine because we’re so far ahead of the curve.” The acquisition by Germfree in 2024 was a milestone that validated Arcoplast’s mission and values. “It wasn’t just any acquisition. It was by a client that I deeply respect. We made each other better over many years,” he reflected. As he steps away, Ghislain leaves Arcoplast in the capable hands of Steve Sebastian, a leader he describes as humble, brilliant, and deeply respected. “What took me a lifetime to learn, he’s mastered in five years,” Ghislain said. “I couldn’t ask for a better person to lead the next chapter.”

“Ghislain’s impact on Arcoplast and the industry is immeasurable. His ability to see opportunity where others saw limitation has shaped not only Arcoplast but also Germfree and the standards of our field. I’m honored to carry forward his legacy and excited to work alongside the next generation of talent at both Germfree and Arcoplast. The future is bright, the combination of our teams is unstoppable, and we’re just getting started. Please join us in celebrating Ghislain’s extraordinary career and the exciting road ahead for Arcoplast!” stated Kevin Kyle, CEO of Germfree.

To our customers, partners, and team: Arcoplast’s mission remains unchanged. The foundation is strong, the leadership is solid, and the future is bright. Ghislain’s legacy will continue to inspire us as we build on his vision—creating environments that stand the test of time.

About Germfree
Germfree Laboratories has become a globally recognized authority in cutting-edge critical environment equipment, cleanrooms, and laboratories for over six decades. The company has consistently led the way in pioneering cleanroom design and manufacturing, serving the biopharmaceutical, healthcare, and research sectors. Germfree remains resolutely committed to providing innovative solutions that significantly improve patient access to life-changing therapies. Germfree is backed by the healthcare growth equity investor, EW Healthcare Partners. Learn more about partnering with Germfree at www.germfree.com.

About Arcoplast
Arcoplast has an international reputation as an industry leader in the field of high containment and controlled environments. Arcoplast earned its reputation by meeting compliancy standards all around the world, passing numerous laboratory tests, and enduring over 30 years real time scientific and industrial workloads.

SOURCE Germfree Laboratories LLC

About Germfree

The post Celebrating Retirement: Ghislain Beauregard’s Legacy and the Future of Arcoplast appeared first on Germfree.

King Faisal Specialist Hospital & Research Centre and Germfree Laboratories Announce Landmark Advanced Therapy Manufacturing Campus in Riyadh

Trinity Pierce — Wed, 18 Jun 2025 13:48:54 +0000

King Faisal Specialist Hospital & Research Centre and Germfree Laboratories Announce Landmark Advanced Therapy Manufacturing Campus in Riyadh

- Unveiled at BIO 2025 in Boston, the project marks a major step toward Saudi Arabia's goal to become a global biotechnology hub by 2040.

Boston, MA, June 17, 2025 – At the BIO International Convention 2025 in Boston, King Faisal Specialist Hospital & Research Centre (KFSHRC) and Germfree Laboratories, LLC announced a strategic partnership to develop Saudi Arabia’s first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.

The new facility will be located at KFSHRC’s main campus in Riyadh and will serve as a critical milestone in advancing Vision 2030 and the National Biotechnology Strategy, two national initiatives aimed at transforming the Kingdom into a global hub for life sciences, biomanufacturing, and to become a global biotech hub by 2040.

“This initiative marks a historic milestone, not just for our institution, but for the Kingdom of Saudi Arabia in alignment with Vision 2030 and the National Biotechnology Strategy,” said His Excellency Dr. Majid bin Ibrahim Al Fayyadh, CEO of KFSHRC. “With Germfree as our partner, we are creating a world-class advanced therapies campus that will accelerate access to transformative treatments, draw the brightest minds in science, and strengthen Saudi Arabia’s position as a global leader in biotechnology. This fast-track, strategic project represents a continuation of the long history of healthcare innovation that has been realized by King Faisal Specialist Hospital and Research Centre.”

“KFSHRC’s leadership and vision align with Germfree’s mission to expand access to complex therapies through future-proofed, agile infrastructure,” said Kevin Kyle, CEO of Germfree Laboratories. “Together, we are building much more than a facility for Cell & Gene Therapy manufacturing, we’re building a turnkey, scalable platform for discovery and delivery of curative therapies for the people of Saudi Arabia, the Middle East, and beyond. This collaboration reflects the critical role infrastructure plays in unlocking access to advanced therapies, and we are proud to support KFSHRC’s vision for patient-centric care.”

Under the terms of a signed Letter of Intent, the turnkey project will fast-track the Kingdom’s ability to manufacture cell and gene therapies locally, host international clinical trials, and attract leading pharmaceutical partnerships and scientific talent from around the world.

Driving Saudi Arabia's Vision for Global Biotech Leadership

This project directly supports Saudi Arabia’s National Biotechnology Strategy, launched to localize vaccine and therapeutic production, develop sovereign biomanufacturing capabilities, and establish the Kingdom as a global biotechnology leader by 2040.

As a core pillar of Vision 2030, the strategy aims to make Saudi Arabia a destination for clinical trials, scientific discovery, pharmaceutical investment, and biotech entrepreneurship across the Middle East and beyond.

By establishing a globally competitive manufacturing campus, KFSHRC is not only advancing national healthcare; it is setting a new global standard for innovation, scalability, and patient-centered care.

A Smart, Scalable Biomanufacturing Platform

The ATMP Manufacturing Campus will be delivered as a fully CGMP-compliant, off-site built, modular solution, developed in strategic phases to support immediate clinical impact and long-term growth.

The project will begin with the deployment of Germfree’s BioGO^®Box single-module cleanroom solution, enabling early operator training, tech transfer, and R&D activities.

In parallel, a newly constructed facility will be built centrally on the KFSHRC campus to house prefabricated modular cleanroom clusters, providing 16 production suites, each designed for multi-modal CGT production supporting both clinical and commercial-scale manufacturing. Full operational readiness will be reached just 18 months after contract signing, roughly half the timeline of a conventional stick-built facility of comparable scope. That speed, combined with the flexibility to scale or repurpose suites as new therapies emerge, means Saudi patients will gain access to advanced treatments years sooner than traditional construction would allow.

The state-of-the-art facility will meet SFDA, FDA, EMA, and BMBL requirements and will include a fully integrated digital manufacturing platform designed to support smart, data-driven CGMP operations from day one.

Germfree’s continued growth is supported by EW Healthcare Partners, a leading private equity company that makes growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and Europe.

About King Faisal Specialist Hospital & Research Centre (KFSHRC)

King Faisal Specialist Hospital & Research Centre is Saudi Arabia’s foremost tertiary-and-quaternary referral institution, delivering world-class care in oncology, transplantation, cardiovascular medicine and precision therapeutics. It is ranked No. 1 in the Middle East & Africa and 15th globally among academic medical centers by Brand Finance’s 2025 report and is listed on Newsweek’s World’s Best Hospitals as well as World’s Best Smart Hospitals 2025. As a flagship partner in the Kingdom’s Vision 2030 and National Biotechnology Strategy an initiative to localize biomanufacturing and make Saudi Arabia a global biotech hub by 2040, KFSHRC forges international collaborations, drives cutting-edge clinical research, and cultivates Saudi scientific talent to expand patient access to life-changing therapies.

About Germfree

The post King Faisal Specialist Hospital & Research Centre and Germfree Laboratories Announce Landmark Advanced Therapy Manufacturing Campus in Riyadh appeared first on Germfree.

Germfree Launches Smarthood™: A Groundbreaking, Software-Agnostic IV Workflow Solution Transforming Sterile Compounding

Trinity Pierce — Mon, 09 Dec 2024 15:06:36 +0000

Germfree Launches Smarthood: A Groundbreaking, Software-Agnostic IV Workflow Solution Transforming Sterile Compounding

- Smarthood is the first solution to integrate IV workflow software, hardware, and peripherals directly into the hood enhancing best practices, bolstering safety, and streamlining the entire workflow.

Ormond Beach, FL, Dec. 9, 2024 – Germfree, a pioneering leader in modular and mobile cleanroom infrastructure, equipment, and services, today announced the launch of Smarthood, the world’s first software-agnostic, fully integrated intravenous (IV) workflow hardware solution. Smarthood is designed to solve persistent challenges in sterile compounding by uniting advanced technologies into a single platform that minimizes contamination risks, reduces workflow errors, and streamlines operations for pharmacists and technicians. *

For more than two decades, industry standards and regulations have evolved to prevent the compounding errors of the past. To achieve a truly effective IV workflow management system, hardware and software must be integrated to support a robust and safe sterile compounding process. Merely adding hardware to an already flawed workflow will not unlock the system’s full potential. Instead, hardware should elevate a good process into a great one.

As a comprehensive platform that integrates primary engineering controls and technology, Smarthood addresses poor aseptic technique caused by fragmented IV workflow implementation. It seamlessly connects all necessary hardware components with the pharmacy’s software of choice. By doing so, Smarthood helps healthcare systems avoid the challenges of assembling and maintaining multiple disjointed components. This ensures consistent practices, reduces variability, and leverages resources efficiently across multiple sites.

“The concept behind Smarthood was born from the need to bridge critical gaps in compounding practices,” said Judd Baker, VP of Healthcare Innovation at Germfree. “By integrating technology directly into the hood itself, Smarthood provides a level of accuracy, efficiency, and patient safety that’s truly unprecedented. From real-time video monitoring to gravimetric analysis, this comprehensive solution delivers everything the modern pharmacy needs to meet today’s challenges.”

“An ideal workflow management system should integrate seamlessly into the compounding environment, enable hands-free operation, utilize hardware components free of excess cabling, and work smoothly with the selected software or electronic health record— all without disrupting the aseptic processing environment or critical airflow,” said Kevin Hansen, Senior Director, Pharmacy Compounding Services at Premier Inc. and Smarthood advisor.

For a Smarthood demo, visit Germfree at booth #1819 during the American Society of Health System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition, from December 8 – 12, 2024 in New Orleans, LA.

For more on Smarthood by Germfree, click here.

Media Contacts:
Lauren Blum, Content Marketing Manager
marketing@germfree.com
SOURCE Germfree Laboratories LLC

Smarthood: A Breakthrough for Patient Safety and Compounding Efficiency

Smarthood addresses the increasingly stringent requirements for sterile compounding at hospital pharmacies, driving standard practices without the need for a piecemeal “Frankenstein” IV workflow from disparate hardware vendors. This solution is set to tackle challenges in sterile compounding that lowers contamination risks, minimizes workflow errors, and enhances efficiency for pharmacists and technicians.

Contamination Risks: Contamination risks in sterile compounding often arise from human error, improper handling, or external factors that compromise the sterile environment.
– Smarthood reduces contamination risks by incorporating advanced technology such as barcode scanning and built-in cameras, ensuring strict adherence to sterile procedures and minimizing human error.

Workflow Errors: Workflow errors occur due to inconsistent processes, poorly integrated systems, or lack of standardization, leading to confusion and inefficiency in compounding.
– Smarthood addresses workflow errors by standardizing processes within a unified system, allowing for better organization, real-time updates, and a smoother, error-free workflow for pharmacists and technicians.

Operational Efficiency: Inefficient operations in sterile compounding can result from outdated or fragmented equipment, leading to unnecessary delays and loss of productivity.
– Smarthood streamlines operations by integrating all necessary equipment, such as barcode scanners, cameras, and computers, into a single, user-friendly system that speeds up tasks and reduces time spent on each compounding procedure.

About Germfree

The post Germfree Launches Smarthood™: A Groundbreaking, Software-Agnostic IV Workflow Solution Transforming Sterile Compounding appeared first on Germfree.

75% of Hospitals Face Medication Shortages – Germfree and On Demand Pharmaceuticals Partner to Deliver Localized Production Solutions

Trinity Pierce — Tue, 03 Dec 2024 16:42:38 +0000

75% of Hospitals Face Medication Shortages – Germfree and On Demand Pharmaceuticals Partner to Deliver Localized Production Solutions

- Partners working to expand program after successful six-month pilot study at North Mississippi Medical Center, which enabled production of 12,000 doses of multiple drugs in limited supply

Ormond Beach, FL, Nov. 12, 2024 – Germfree Laboratories, On Demand Pharmaceuticals (ODP), and North Mississippi Medical Center-Tupelo (NMMC) have teamed up to address the global drug shortage crisis with a groundbreaking point-of-care medicine production solution. The expanding partnership aims to bring agile production of essential medicines closer to the point of care across the country and globally, ensuring a reliable supply of life-saving drugs.

With more than 75% of U.S. hospitals facing medication shortages and millions of people in low- and middle-income countries lacking access to critical medicines, the need for localized, flexible production is urgent. By combining Germfree’s mobile cleanroom technology with ODP’s Pharmacy on Demand platform, this collaboration empowers healthcare providers to produce high-quality medications on site, reducing reliance on fragile global supply chains.

The partnership builds on a six-month pilot study that leveraged ODP’s platform technology and Germfree’s mobile cleanroom capability to produce syringes of common shortage medicines at NMMC, including lidocaine, rocuronium, and potassium chloride. This real-world pilot met all regulatory requirements, leveraged a state-of-the art quality management approach, and demonstrated a novel, agile compounding capability for drugs on shortage. It resulted in patients being treated with high-quality medicines that were made on-demand and on-site.

“We’re not just filling gaps in the supply chain, we’re redefining it,” said Kevin Kyle, CEO of Germfree. “With On Demand Pharma, we are enabling healthcare providers to meet patient needs faster and more reliably, whether in urban centers or rural areas. This partnership also demonstrates our commitment to using cutting-edge technologies to improve the way hospital pharmacies respond to the needs of their patients, with more to come.”

Matt Pietras, CEO of On Demand Pharmaceuticals, added, “This collaboration with Germfree provides us with the high-quality modular infrastructure needed to provide our Medication-as-a-Service (MaaS) where patients and healthcare providers need it most.”

The innovative model will allow hospitals like NMMC to produce critical medications locally, improving access for patients and ensuring continuity of care even during global supply disruptions. “Our pilot work completed through this collaboration has proven these new capabilities for on-site compounded medications are able to help us better serve our communities in a timelier manner,” said Wes Pitts, System Director of Pharmacy at North Mississippi Health Services, which includes NMMC in Tupelo. “In our pilot program, we were able to successfully compound approximately 12,000 doses of shortage medications starting in December 2023 following regulations from the Board of Pharmacy.”

“We are on the cusp of expanding distributed medicine production through our network while creating a new paradigm,” said John Lewin, Chief Medical Officer at ODP. “I envision a future where pharmacists take a leading role in medicine production – both today and as personalized medicine becomes the standard at the point of care.”

The collaboration between Germfree and On Demand Pharmaceuticals is set to transform the future of medicine accessibility by providing healthcare providers with the tools to produce medications on demand, whenever and wherever they are needed.

About Germfree Laboratories: Germfree Laboratories is a global leader in cleanroom and critical environment technologies, specializing in providing innovative solutions for biopharmaceutical, healthcare, and research sectors. Learn more at www.germfree.com.

About On Demand Pharmaceuticals: On Demand Pharmaceuticals (ODP) is revolutionizing pharmaceutical access with its Pharmacy on Demand platform, offering agile, on-site production of medications. ODP is committed to overcoming industry barriers and ensuring high-quality medicines are accessible to all. Learn more at www.ondemandpharma.com.

About North Mississippi Medical Center: North Mississippi Medical Center (NMMC) is one of the largest non-metropolitan hospitals in the U.S., providing comprehensive medical services to a growing community. NMMC is committed to innovation in healthcare delivery to ensure high-quality, accessible care for its patients. For more information, visit www.nmhs.net.

SOURCE Germfree Laboratories LLC

Media Contacts:
Germfree Laboratories:
Lauren Blum, Content Marketing Manager
marketing@germfree.com

On Demand Pharmaceuticals:
Media Relations
media@ondemandpharma.com

North Mississippi Medical Center:
Deborah Pugh
drpugh@nmhs.net

About Germfree

The post 75% of Hospitals Face Medication Shortages – Germfree and On Demand Pharmaceuticals Partner to Deliver Localized Production Solutions appeared first on Germfree.